Literature DB >> 26928243

Pathogenesis of Nonalcoholic Steatohepatitis.

Mariana Verdelho Machado1, Anna Mae Diehl2.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a necro-inflammatory response that ensues when hepatocytes are injured by lipids (lipotoxicity). NASH is a potential outcome of nonalcoholic fatty liver (NAFL), a condition that occurs when lipids accumulate in hepatocytes. NASH may be reversible, but it can also result in cirrhosis and primary liver cancer. We are beginning to learn about the mechanisms of progression of NAFL and NASH. NAFL does not inevitably lead to NASH because NAFL is a heterogeneous condition. This heterogeneity exists because different types of lipids with different cytotoxic potential accumulate in the NAFL, and individuals with NAFL differ in their ability to defend against lipotoxicity. There are no tests that reliably predict which patients with NAFL will develop lipotoxicity. However, NASH encompasses the spectrum of wound-healing responses induced by lipotoxic hepatocytes. Differences in these wound-healing responses among individuals determine whether lipotoxic livers regenerate, leading to stabilization or resolution of NASH, or develop progressive scarring, cirrhosis, and possibly liver cancer. We review concepts that are central to the pathogenesis of NASH.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lipotoxicity; Misrepair; Nonalcoholic Fatty Liver Disease; Wound-Healing Response

Mesh:

Substances:

Year:  2016        PMID: 26928243      PMCID: PMC4887389          DOI: 10.1053/j.gastro.2016.02.066

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  76 in total

1.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

2.  Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Authors:  Cynthia D Guy; Ayako Suzuki; Marzena Zdanowicz; Manal F Abdelmalek; James Burchette; Aynur Unalp; Anna Mae Diehl
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

3.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

4.  Increased production of sonic hedgehog by ballooned hepatocytes.

Authors:  Fatima Rangwala; Cynthia D Guy; Jiuyi Lu; Ayako Suzuki; James L Burchette; Manal F Abdelmalek; Wei Chen; Anna Mae Diehl
Journal:  J Pathol       Date:  2011-05-05       Impact factor: 7.996

5.  Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate.

Authors:  Hiroyuki Nojima; Christopher M Freeman; Rebecca M Schuster; Lukasz Japtok; Burkhard Kleuser; Michael J Edwards; Erich Gulbins; Alex B Lentsch
Journal:  J Hepatol       Date:  2015-08-05       Impact factor: 25.083

6.  Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice.

Authors:  Guanhua Xie; Gamze Karaca; Marzena Swiderska-Syn; Gregory A Michelotti; Leandi Krüger; Yuping Chen; Richard T Premont; Steve S Choi; Anna Mae Diehl
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

7.  Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis.

Authors:  Steve S Choi; Alessia Omenetti; Rafal P Witek; Cynthia A Moylan; Wing-Kin Syn; Youngmi Jung; Liu Yang; Debra L Sudan; Jason K Sicklick; Gregory A Michelotti; Marcos Rojkind; Anna Mae Diehl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-08       Impact factor: 4.052

8.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

Review 9.  Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.

Authors:  Claudia Filozof; Barry J Goldstein; Richard N Williams; Arun Sanyal
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

10.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

Authors:  Bi-Sen Ding; Zhongwei Cao; Raphael Lis; Daniel J Nolan; Peipei Guo; Michael Simons; Mark E Penfold; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  134 in total

1.  Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.

Authors:  Pooja Malhotra; Costica Aloman; Aparna Ankireddy; Hani Khadra; Kohtaro Ooka; Ravinder K Gill; Seema Saksena; Pradeep K Dudeja; Waddah A Alrefai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-08-03       Impact factor: 4.052

2.  MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.

Authors:  Yong He; Seonghwan Hwang; Yan Cai; Seung-Jin Kim; Mingjiang Xu; Dingcheng Yang; Adrien Guillot; Dechun Feng; Wonhyo Seo; Xin Hou; Bin Gao
Journal:  Hepatology       Date:  2019-06-05       Impact factor: 17.425

3.  Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.

Authors:  Zengsheng Lu; Fengbin Lu; Liyan Wu; Beihui He; Zhiyun Chen; Maoxiang Yan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-10       Impact factor: 3.000

4.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

5.  Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model.

Authors:  Yoon Mee Yang; Zhijun Wang; Michitaka Matsuda; Ekihiro Seki
Journal:  Arch Pharm Res       Date:  2021-01-24       Impact factor: 4.946

6.  Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy.

Authors:  Yu Wang; Geng Wang; Jie Bai; Ning Zhao; Qingbo Wang; Rui Zhou; Gang Li; Chaojie Hu; Xin Li; Kaixiong Tao; Zefeng Xia; Guobin Wang
Journal:  Obes Surg       Date:  2021-05-10       Impact factor: 4.129

7.  Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.

Authors:  Jason S Seidman; Ty D Troutman; Mashito Sakai; Anita Gola; Nathanael J Spann; Hunter Bennett; Cassi M Bruni; Zhengyu Ouyang; Rick Z Li; Xiaoli Sun; BaoChau T Vu; Martina P Pasillas; Kaori M Ego; David Gosselin; Verena M Link; Ling-Wa Chong; Ronald M Evans; Bonne M Thompson; Jeffrey G McDonald; Mojgan Hosseini; Joseph L Witztum; Ronald N Germain; Christopher K Glass
Journal:  Immunity       Date:  2020-05-01       Impact factor: 31.745

8.  Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial.

Authors:  Maret G Traber; Eunice Mah; Scott W Leonard; Gerd Bobe; Richard S Bruno
Journal:  Am J Clin Nutr       Date:  2017-01-11       Impact factor: 7.045

Review 9.  The hedgehog pathway in nonalcoholic fatty liver disease.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-03-20       Impact factor: 8.250

10.  PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.

Authors:  Wenfeng Zhang; Yan Liu; Mingbing Wu; Xiwen Zhu; Tao Wang; Kun He; Peizhi Li; Xiaoling Wu
Journal:  J Physiol Biochem       Date:  2017-09-13       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.